论文部分内容阅读
第5 3届ACC年会心律失常领域最大的亮点,莫过于三个大型临床试验的公布,尤其是SCD HeFT(SuddenCardiacDeathinHeartFailureTrial)试验的结果令人瞠目,对于射血分数(EF)值≤0 .35的心功能Ⅱ～Ⅲ级慢性心力衰竭(简称心衰)患者,预防性应用胺碘酮治疗6 0个月患者的病死率竟然与安慰
The biggest bright spot in the field of arrhythmia at the 53rd ACC annual meeting was the announcement of three large-scale clinical trials. In particular, the results of the SCD HeFT (Sudden Cardiac Death in Heart Failure Trial) were striking. For ejection fraction (EF) ≤0.35 Of patients with heart function Ⅱ ~ Ⅲ chronic heart failure (referred to as heart failure), prophylactic amiodarone 60 months of patients with mortality and comfort